Transforming treatments for schizophrenia: Investigating changes in Electroencephalogram (EEG) theta spectral power at the right temperoparietal junction (rTPJ) following combined virtual reality and theta tACS.

Monash University0 sites46 target enrollmentDecember 1, 2021

Overview

No summary available.

Registry

who.int

Start Date

December 1, 2021

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional

Sex

All

Sponsor

•Participants with a diagnosis of schizophrenia or schizoaffective disorder:
•\-Adults between 18 and 55 years of age.
•\-Diagnosis of schizophrenia or schizoaffective disorder as confirmed by the MINI 7\.0\.2\.
•\-Ability to provide informed consent and show understanding of participation by relaying key information to researcher.
•Healthy Volunteers:
•\-Adults aged 18\-55 years
•\-No history of mental illness confirmed with MINI
•\-No unstable medical conditions
•\-No contraindications to receiving tACS (mentioned in exclusion criteria)

•\-Commencement or significant dosage alteration of other psychotropic medications (i.e., anti\-depressants, anti\-psychotics) during the four weeks prior to an experimental session.
•\-Currently taking any medication shown to interfere with the effects of tACS; namely benzodiazepines
•\-A current substance use or alcohol use disorder
•\-Any history of significant head injury or traumatic brain injury, as defined by a loss of consciousness greater than 30 minutes or requiring a hospital admission.
•\-Unstable medical or neurological illness.
•\-Pregnancy or breastfeeding.
•\-An uncorrected hearing or visual impairment (including difficulty with colour perception).
•\-Significant difficulties with understanding or communicating in English.